Insmed (NASDAQ:INSM) Releases Quarterly Earnings Results, Misses Estimates By $0.15 EPS

Insmed (NASDAQ:INSM) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15), Zacks reports. Insmed updated its FY 2025 guidance to EPS.

Insmed Trading Down 1.0 %

Shares of NASDAQ INSM traded down $0.81 during midday trading on Thursday, hitting $83.02. The stock had a trading volume of 822,529 shares, compared to its average volume of 1,878,880. The company has a market capitalization of $14.85 billion, a price-to-earnings ratio of -15.06 and a beta of 1.11. Insmed has a 1-year low of $21.92 and a 1-year high of $83.99. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The company has a fifty day moving average price of $73.87 and a 200 day moving average price of $73.45.

Insider Activity

In other Insmed news, insider Martina M.D. Flammer sold 3,344 shares of Insmed stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the sale, the insider now directly owns 102,766 shares in the company, valued at $6,773,307.06. The trade was a 3.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sara Bonstein sold 1,066 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.72, for a total value of $67,925.52. Following the completion of the sale, the chief financial officer now owns 118,863 shares of the company’s stock, valued at $7,573,950.36. This trade represents a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 495,135 shares of company stock valued at $38,409,713 in the last three months. Corporate insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

INSM has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Wells Fargo & Company raised their target price on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday. Truist Financial restated a “buy” rating and issued a $105.00 price target (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Guggenheim lifted their price objective on Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Finally, Stifel Nicolaus lifted their price objective on Insmed from $88.00 to $97.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.86.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.